Emodin inhibits migration and invasion of MHCC-97H human hepatocellular carcinoma cells

Ferlay, 2010, Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008, Int J Cancer, 127, 2893, 10.1002/ijc.25516

Forner, 2012, Hepatocellular carcinoma, Lancet, 379, 1245, 10.1016/S0140-6736(11)61347-0

Bosetti, 2014, Hepatocellular carcinoma epidemiology, Best Pract Res Clin Gastroenterol, 28, 753, 10.1016/j.bpg.2014.08.007

Maluccio, 2012, Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma, CA Cancer J Clin, 62, 394, 10.3322/caac.21161

Forner, 2010, Current strategy for staging and treatment: The BCLC update and future prospects, Semin Liver Dis, 30, 61, 10.1055/s-0030-1247133

Baffy, 2015, Decoding multifocal hepatocellular carcinoma: An opportune pursuit, Hepatobiliary Surg Nutr, 4, 206

Lui, 2015, Targeting cancer by binding iron: Dissecting cellular signaling pathways, Oncotarget, 6, 18748, 10.18632/oncotarget.4349

Ling, 2014, Three advantages of using traditional Chinese medicine to prevent and treat tumor, J Integr Med, 12, 331, 10.1016/S2095-4964(14)60038-8

Li, 2014, Role of traditional Chinese medicine and its chemical components in anti-tumor metastasis, J Cancer Res Ther, 10, S20

Wang, 2015, Chinese medicines for prevention and treatment of human hepatocellular carcinoma: Current progress on pharmacological actions and mechanisms, J Integr Med, 13, 142, 10.1016/S2095-4964(15)60171-6

Sun, 2012, Downregulation of phosphatase of regenerating liver-3 is involved in the inhibition of proliferation and apoptosis induced by emodin in the SGC-7901 human gastric carcinoma cell line, Exp Ther Med, 3, 1077, 10.3892/etm.2012.516

Shrimali, 2013, Targeted abrogation of diverse signal transduction cascades by emodin for the treatment of inflammatory disorders and cancer, Cancer Lett, 341, 139, 10.1016/j.canlet.2013.08.023

Zhang, 2015, Effects of emodinon the demethylation of tumor-suppressor genes in pancreatic cancer PANC-1 cells, Oncol Rep, 33, 3015, 10.3892/or.2015.3914

Pooja, 2014, Emodin suppresses Wnt signaling in human colorectal cancer cells SW480 and SW620, Eur J Pharmacol, 742, 55, 10.1016/j.ejphar.2014.08.028

Ma, 2015, The anthraquinone derivative Emodin inhibits angiogenesis and metastasis through downregulating Runx2 activity in breast cancer, Int J Oncol, 46, 1619, 10.3892/ijo.2015.2888

Wei, 2013, The distinct mechanisms of the antitumor activity of emodin in different types of cancer (Review), Oncol Rep, 30, 2555, 10.3892/or.2013.2741

Subramaniam, 2013, Emodin inhibits growth and induces apoptosis in an orthotopic hepatocellular carcinoma model by blocking activation of STAT3, Br J Pharmacol, 170, 807, 10.1111/bph.12302

Manu, 2013, Emodin suppresses migration and invasion through the modulation of CXCR4 expression in an orthotopic model of human hepatocellular carcinoma, PloS One, 8, e57015, 10.1371/journal.pone.0057015

Polacheck, 2013, Tumor cell migration in complex microenvironments, Cell Mol Life Sci, 70, 1335, 10.1007/s00018-012-1115-1

Deryugina, 2015, Tumor angiogenesis: MMP-mediated induction of intravasation-and metastasis-sustaining neovasculature, Matrix Biol 44–46, 94, 10.1016/j.matbio.2015.04.004

Kessenbrock, 2015, Matrix metalloproteinases in stem cell regulation and cancer, Matrix Biol 44–46, 184, 10.1016/j.matbio.2015.01.022

Daniele, 2014, Clinical and prognostic role of circulating MMP-2 and its inhibitor TIMP-2 in HCC patients prior to and after trans-hepatic arterial chemo-embolization, Clin Biochem, 47, 184, 10.1016/j.clinbiochem.2013.11.022

Chen, 2012, The significance of MMP-9 over MMP-2 in HCC invasiveness and recurrence of hepatocellular carcinoma after curative resection, Ann Surg Oncol, 19, S375, 10.1245/s10434-011-1836-7

Peti, 2013, Molecular basis of MAP kinase regulation, Protein Sci, 22, 1698, 10.1002/pro.2374

Lin, 2014, MST4 promotes hepatocellular carcinoma epithelial-mesenchymal transition and metastasis via activation of the p-ERK pathway, Int J Oncol, 45, 629, 10.3892/ijo.2014.2455

Grossi, 2014, p38α MAPK pathway: A key factor in colorectal cancer therapy and chemoresistance, World J Gastroenterol, 20, 9744, 10.3748/wjg.v20.i29.9744

Kim, 2015, Compromised MAPK signaling in human diseases: An update, Arch Toxicol, 89, 867, 10.1007/s00204-015-1472-2

Olson, 2004, p38 MAP kinase: A convergence point in cancer therapy, Trends Mol Med, 10, 125, 10.1016/j.molmed.2004.01.007

Koul, 2013, Role of p38 MAP kinase signal transduction in solid tumors, Genes Cancer, 4, 342, 10.1177/1947601913507951

Engelman, 2009, Targeting PI3K signalling in cancer: Opportunities, challenges and limitations, Nat Rev Cancer, 9, 550, 10.1038/nrc2664

Lin, 2014, 11-epi-Sinulariolide acetate reduces cell migration and invasion of human hepatocellular carcinoma by reducing the activation of ERK1/2, p38MAPK and FAK/PI3K/AKT/mTOR signaling pathways, Mar Drug, 12, 4783, 10.3390/md12094783

Schmitz, 2008, Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection, J Hepatol, 48, 83, 10.1016/j.jhep.2007.08.018

Wu, 2015, Sinulariolide suppresses human hepatocellular carcinoma cell migration and invasion by inhibiting matrix metalloproteinase-2/-9 through MAPKs and PI3K/Akt signaling pathways, Int J Mol Sci, 16, 16469, 10.3390/ijms160716469